Helus Pharma CEO Will Discuss Depression Drug Progress
The company head will preview updates on Phase 3 trials for a serotonin-based treatment for depression and anxiety.
Updated on Sept. 21, 2026 in Mental Health
Helus Pharma CEO Michael Halstead is scheduled to participate in a live webcast fireside chat on September 23, 2026. The discussion will highlight the latest progress on the company's novel serotonin-focused drug candidates.
Why it matters
The company is exploring new ways to treat depression and anxiety by utilizing synthetic molecules designed to target serotonin pathways. These candidates aim to address significant unmet needs in mental health care.
Helus Pharma is currently moving HLP003 through Phase 3 clinical development while evaluating HLP004 in Phase 2. Both candidates are synthetic serotonergic agonists intended to target unmet clinical needs.
The players
Helus Pharma
A pharmaceutical company that develops synthetic molecules for depression and anxiety.
Michael Halstead
The CEO of Helus Pharma who is slated to speak on the company's research pipeline.
U.S. Food and Drug Administration
The federal agency that regulates drug safety and granted Breakthrough Therapy Designation to HLP003.
The details
The development pipeline focuses on synthesizing molecules that act as agonists to activate serotonin pathways in the brain. By specifically targeting these neural routes, the company aims to provide alternatives for patients with treatment-resistant depression and anxiety. This mechanism differs from traditional methods by attempting to refine how serotonin signaling is initiated.
Timeline
September 23, 2026, at 9:00 a.m. EDT
Health Landscape
The development of novel serotonergic agonists follows a broader trend of leveraging specific brain signaling pathways to improve mental health outcomes. This effort sits alongside the FDA Breakthrough Therapy Designation program, which seeks to fast-track treatments for conditions lacking adequate therapies.
While these developments are early-stage, patients with depression or anxiety may wish to keep track of pipeline announcements to discuss potential future trial eligibility with their physician. It remains important to consult a doctor before considering any experimental or new-to-market treatments.
The takeaway
Advancements in serotonin-targeted molecules represent a potential shift in how depression and anxiety are treated in the clinical setting. Patients should monitor major regulatory updates and consult with a mental health professional to stay informed about standard-of-care options.
Further reading
For more information on how new psychiatric medications are evaluated, visit the Mental Health section.
